NHL

FDA begins speedy review of BMS’ CAR-T liso-cel

The US Food and Drug Administration has accepted an application for Bristol-Myers Squibb’s CAR-T therapy lisocabtagene maraleucel, kick-starting a priority review of the drug.
Liso-cel is a novel treatment for relapsed/refractory large B-cell lymphoma…